WhatsApp

What Affects Survival After Surgery for Retroperitoneal Leiomyosarcoma?

You are here >> Home > Latest Updates > Retroperitoneal Cancer > What Affects…

The prognosis factors landscape of surgical management of retroperitoneal leiomyosarcoma A retrospective multicenter study.DOI 10.1016j.amjsurg.2025.116647

Retroperitoneal leiomyosarcoma (RLMS) is a rare cancer that grows deep in the abdomen. Surgery is the main treatment, but it can be hard to know how long someone might live after treatment—especially if the cancer comes back.

Doctors looked at the records of 227 patients who had surgery for RLMS over 20 years. Some had their first surgery, and others had surgery for a cancer recurrence. They wanted to find what factors affect how long patients survive after surgery.

People treated for the first time lived a median of 62 months. Those who had surgery for recurrent cancer lived about 33 months. Even in the recurrent group, some lived much longer, showing that surgery can still help.

In both groups, the number of white blood cells, platelets, and the time between surgeries mattered. In particular, a blood test called the neutrophil-to-lymphocyte ratio (NLR) was linked to survival. A lower NLR usually meant better outcomes. For people with recurring RLMS, a longer break between treatments was also a good sign.

These results show that certain lab results and how long the cancer stays away after treatment can help doctors predict outcomes. It may also guide decisions about whether to do another surgery if the cancer comes back.

Rate this post

Exclusive Health Tips and Updates

dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.